| Trial ID: | L0212 |
| Source ID: | NCT02837237
|
| Associated Drug: |
Kbp-5074
|
| Title: |
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02837237/results
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: KBP-5074
|
| Outcome Measures: |
Primary: Number of Participants With Treatment-related Adverse Events, Physical exam, vital signs, EKG, clinical laboratory tests, adverse events, 312 hours |
|
| Sponsor/Collaborators: |
Sponsor: KBP Biosciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
11
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-07-13
|
| Completion Date: |
2017-06-30
|
| Results First Posted: |
2019-10-15
|
| Last Update Posted: |
2024-03-15
|
| Locations: |
KBP Biosciences USA Inc, Princeton, New Jersey, 08540, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02837237
|
